Evidence map›Paper›PMID 35650373›Full record

ReviewCurrent rheumatology reports2022

Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know.

Elena K Joerns, Traci N Adams, Jeffrey A Sparks, Chad A Newton, Bonnie Bermas, David Karp, Una E Makris

Open access · bronzeAbstract readReview
In one paragraph

Review in Current rheumatology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Elena K JoernsDepartment of Internal Medicine, Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, 6011 Harry Hines Blvd, Dallas, TX, 75390, USA. elena.joerns@utsouthwestern.edu.ORCID http://orcid.org/0000-0001-7089-9152
Traci N AdamsDepartment of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jeffrey A SparksDepartment of Medicine, Division of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Chad A NewtonDepartment of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Bonnie BermasDepartment of Internal Medicine, Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, 6011 Harry Hines Blvd, Dallas, TX, 75390, USA.
David KarpDepartment of Internal Medicine, Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, 6011 Harry Hines Blvd, Dallas, TX, 75390, USA.
Una E MakrisDepartment of Internal Medicine, Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, 6011 Harry Hines Blvd, Dallas, TX, 75390, USA.
The University of Texas Southwestern Medical Center · USBrigham and Women's Hospital · USSouthwestern Medical Center · USVeterans Health Administration · US

Funding

VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8M
Joint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4M
TRAINING PROGRAM IN LUNG BIOLOGY AND DISEASET32HL098040 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAUL, PHILIP W, TERADA, LANCE S · 2009 to 2024
$4.6M
Rheumatoid Arthritis-Related Autoantibodies, Articular Inflammation, and RA-Associated Interstitial Lung DiseaseR01AR077607 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SPARKS, JEFFREY ANDREW · 2021 to 2025
$3.7M
Molecular Markers of Idiopathic Pulmonary Fibrosis ProgressionK23HL148498 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI NEWTON, CHAD ALAN · 2020 to 2024
$891k
NHLBI NIH HHS K23 HL148498NHLBI NIH HHS T32 HL098040NIAMS NIH HHS P30 AR070253NIAMS NIH HHS P30 AR072577NIAMS NIH HHS R01 AR077607
6 · The paper itself

Abstract

purpose of reviewThis narrative review will focus on the role of the rheumatologist in evaluating patients with interstitial lung disease (ILD) without a defined rheumatic disease and will outline the current classification criteria for interstitial pneumonia with autoimmune features (IPAF) and describe what is known regarding IPAF pathobiology, natural history, prognosis, and treatment. Lastly, knowledge gaps and opportunities for future research will be discussed. RECENT

findingsIPAF is a recently defined classification of ILD patients who have features suggesting an autoimmune-mediated process, but do not fulfill current rheumatic disease criteria. The goal of the IPAF criteria is to provide a uniform case definition for the study of autoimmune ILD patients who do not currently fit within standard ILD diagnostic categories, ultimately improving diagnosis and therapy. Many of these patients are referred for rheumatologic evaluation to aid the diagnostic process. The care of the IPAF patient is complex and is multidisciplinary with pulmonology, rheumatology, pathology, radiology, physical therapy, primary care, pulmonary transplant providers all serving vital roles. The rheumatologist has several roles which include classification, disease monitoring, and management.

Indexed as

Autoimmune DiseasesLung Diseases, InterstitialRheumatic DiseasesHumansLungRheumatologistsInterstitial lung diseaseInterstitial pneumonia with autoimmune featuresPulmonary rheumatology collaborationRheumatologist evaluation

Identifiers

PMID35650373
PMCPMC9159646
OpenAlexW4281662069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.